Abeona Therapeutics Inc [ABEO] stock is trading at $4.32, down -4.11%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The ABEO shares have lost -2.92% over the last week, with a monthly amount drifted -14.29%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Abeona Therapeutics Inc [NASDAQ: ABEO] stock has seen the most recent analyst activity on March 05, 2025, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $16. Previously, H.C. Wainwright started tracking the stock with Buy rating on July 03, 2024, and set its price target to $15. On May 30, 2024, Stifel initiated with a Buy rating and assigned a price target of $21 on the stock. Cantor Fitzgerald upgraded its rating to a Overweight but stick to its price target of $4 on November 11, 2020. B. Riley FBR initiated its recommendation with a Buy and recommended $5 as its price target on September 18, 2020. SVB Leerink started tracking with a Outperform rating for this stock on February 10, 2020, and assigned it a price target of $6.
Abeona Therapeutics Inc [ABEO] stock has fluctuated between $3.05 and $8.45 over the past year. Currently, Wall Street analysts expect the stock to reach $16 within the next 12 months. Abeona Therapeutics Inc [NASDAQ: ABEO] shares were valued at $4.32 at the most recent close of the market. An investor can expect a potential return of 270.37% based on the average ABEO price forecast.
Analyzing the ABEO fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.59, Equity is -1.65 and Total Capital is -0.7. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.52.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 4.11 points at the first support level, and at 3.89 for the second support level. However, for the 1st resistance point, the stock is sitting at 4.69, and for the 2nd resistance point, it is at 5.05.
Ratios To Look Out For
For context, Abeona Therapeutics Inc’s Current Ratio is 6.08. Further, the Quick Ratio stands at 6.08, while the Cash Ratio is 1.41.
Transactions by insiders
Recent insider trading involved Seshadri Vishwas, Chief Executive Officer, that happened on Mar 31 ’25 when 25000.0 shares were sold. Officer, Seshadri Vishwas completed a deal on Mar 31 ’25 to buy 25000.0 shares. Meanwhile, Director Alvino Mark sold 4000.0 shares on Jan 29 ’25.
